Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr;12(4):629–636. doi: 10.4103/1673-5374.205104

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Neural Regeneration Research

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

PMC Copyright notice

Preliminary test of the sensory functional recovery of rats with mental nerve crush injury assessed by von Frey filaments test after recombinant human fibroblast growth factor-2 (rhFGF2) treatment.

(A, B) A comparison of the gap score (A) and difference score (B) shows little sensory functional recovery in rats with mental nerve crush injury after administration of rhFGF2 at low doses (0.1, 0.2 and 0.4 μg/mL). Decreased gap score and increased difference score mean the presence of sensory degeneration. Sham: Sham-operated (normal control); PBS: PBS treatment after mental nerve crush injury; rhFGF0.1, rhFGF0.2 and rhFGF0.4: rhFGF2 treatment (0.1, 0.2, 0.4 μg/mL, respectively) after mental nerve crush injury. There were six rats per group.